Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID PRESCOTT TIETJEN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1508838384
CMS profile
159288
Location
HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$279.61

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $279.61 18

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID PRESCOTT TIETJEN

NPI 1508838384 · CMS profile ID 159288

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $279.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
OPKO Pharmaceuticals, LLC $15.2611/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238093 CMS
AstraZeneca Pharmaceuticals LP $13.9211/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736383989 CMS
Horizon Therapeutics plc $15.0011/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721448721 CMS
AstraZeneca Pharmaceuticals LP $18.9309/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736274835 CMS
Relypsa, Inc. $13.8409/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742199549 CMS
Novartis Pharmaceuticals Corporation $15.5707/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726160769 CMS
OPKO Pharmaceuticals, LLC $11.9907/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238089 CMS
Alexion Pharmaceuticals, Inc. $14.4607/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726636247 CMS
AKEBIA THERAPEUTICS INC $18.5806/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753171637 CMS
Relypsa, Inc. $12.3105/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742204009 CMS
OPKO Pharmaceuticals, LLC $14.4003/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238095 CMS
AKEBIA THERAPEUTICS INC $16.4903/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753171635 CMS
Otsuka America Pharmaceutical, Inc. $23.0802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748801989 CMS
OPKO Pharmaceuticals, LLC $19.7502/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238091 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.7702/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747312973 CMS
Otsuka America Pharmaceutical, Inc. $16.5701/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748801987 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2001/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747312971 CMS
AstraZeneca Pharmaceuticals LP $12.4901/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736245931 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $462.83 30
PY2020 $279.61 18
PY2021 $646.77 24
PY2022 $630.15 34
PY2023 $655.62 29
PY2024 $538.52 20
PY2025 $311.01 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $86,493.87 37
PY2024 Principal investigator $77,411.65 31
PY2023 Principal investigator $244,765.38 77
PY2022 Principal investigator $437,199.28 132
PY2021 Principal investigator $475,627.60 160
PY2020 Principal investigator $841,410.33 80
PY2019 Principal investigator $476,990.58 451

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $600.00 12/11/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335204
Principal investigator 1 CSL Behring $1,500.00 12/11/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335206
Principal investigator 1 CSL Behring $7,302.00 12/11/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335208
Principal investigator 1 CSL Behring $289.70 12/10/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335800
Principal investigator 1 CSL Behring $484.30 11/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335848
Principal investigator 1 CSL Behring $313.06 10/22/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335584
Principal investigator 1 CSL Behring $150.00 10/07/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335110
Principal investigator 1 CSL Behring $1,500.00 10/07/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335112
Principal investigator 1 CSL Behring $8,800.00 10/07/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335114
Principal investigator 1 CSL Behring $2,000.00 10/07/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335116
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,210.00 09/11/2024 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1089686487
Principal investigator 1 CSL Behring $31.08 09/04/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335646
Principal investigator 1 CSL Behring $4,063.20 08/05/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334946
Principal investigator 1 CSL Behring $17.14 07/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335480
Principal investigator 1 CSL Behring $17.14 07/09/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335450
Principal investigator 1 CSL Behring $450.00 06/19/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334824
Principal investigator 1 CSL Behring $1,905.43 05/28/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335376
Principal investigator 1 CSL Behring $1,562.00 04/19/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334778
Principal investigator 1 CSL Behring $1,919.00 04/19/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334780
Principal investigator 1 CSL Behring $450.00 04/19/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334782
Principal investigator 1 AstraZeneca UK Limited $2,206.00 04/17/2024 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS, LLC
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease No dispute reported 06/30/2026 1110836662
Principal investigator 1 Alexion Pharmaceuticals, Inc. $18,080.00 03/27/2024 Non-covered Recipient Entity
APOGEE CLINICAL RESEARCH LLC
Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1110843362
Principal investigator 1 CSL Behring $600.00 02/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334676
Principal investigator 1 CSL Behring $378.00 02/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334678
Principal investigator 1 CSL Behring $750.00 02/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334710
Principal investigator 1 CSL Behring $548.00 02/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334712
Principal investigator 1 CSL Behring $1,350.00 02/02/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334642
Principal investigator 1 CSL Behring $300.00 02/02/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334644
Principal investigator 1 CSL Behring $189.00 02/02/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334646
Principal investigator 1 CSL Behring $246.60 01/24/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334610
Principal investigator 1 Boehringer Ingelheim International GmbH $13,200.00 01/10/2024 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 1101068583